JPRN-UMIN000019030已完成未知
Multicenter clinical study of immune-cell therapy in patients with malignant tumors. - Multicenter clinical study of immune-cell therapy in patients with malignant tumors.
KOUSHIKAI,Non-profitmedicalcorporation0 个研究点目标入组 1,800 人开始时间: 2015年9月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) HIV Ab positive. 2) T cell- or NK cell-originated leukemia and/or lymphoma.(LAK therapy) 3)Patients who have previously treated allogenic transplantation. 4) Responsible doctors judged the patient inappropriate for the clinical study.
研究者
相似试验
已完成
1 期
A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade gliomagliomaJPRN-UMIN000032147Juntendo University Faculty of Medicine5
进行中（未招募）
不适用
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemiaEUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
进行中（未招募）
不适用
Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. - PRIMAVERAInfection by HPV 6, 11, 16, 18EUCTR2011-006002-27-FRCHU de Bordeaux
已完成
1 期
Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)NCT06296056Seoul Hospital9
已完成
1 期
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18